Literature DB >> 2013383

Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

R H Duerr1, S R Targan, C J Landers, N F LaRusso, K L Lindsay, R H Wiesner, F Shanahan.   

Abstract

Whether serum autoantibodies to neutrophil cytoplasmic components, previously found in ulcerative colitis, are also associated with primary sclerosing cholangitis was determined. In an enzyme-linked immunosorbent assay for immunoglobulin G neutrophil antibodies, neutrophil binding by primary sclerosing cholangitis sera was significantly greater than that for primary biliary cirrhosis, chronic hepatitis B, and chronic non-A, non-B hepatitis. Similar differences were seen when sera from patients with primary sclerosing cholangitis without evidence for ulcerative colitis were compared with sera from liver disease controls. Perinuclear immunofluorescence staining of neutrophils was exhibited by the majority of ulcerative colitis, primary sclerosing cholangitis, and primary sclerosing cholangitis without ulcerative colitis sera. The combination of elevated immunoglobulin G neutrophil antibodies and a perinuclear pattern was 65% sensitive and 100% specific for primary sclerosing cholangitis compared with the liver disease control sera. It is concluded that neutrophil cytoplasmic antibodies in ulcerative colitis and primary sclerosing cholangitis may be markers of shared underlying immunopathogenic mechanisms. Identification of the target antigen(s) may facilitate understanding of the underlying immune response and development of an improved disease marker assay.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013383

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  71 in total

1.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

Review 2.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 3.  Churg-Strauss syndrome.

Authors:  M Conron; H L Beynon
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

4.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 5.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

6.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

7.  Anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel diseases (IBD).

Authors:  T Nakato; M Fukushima; H Yamamoto
Journal:  Gastroenterol Jpn       Date:  1992-10

8.  Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis.

Authors:  Bo Xu; Ulrika Broome; Mehmet Uzunel; Silvia Nava; Xupeng Ge; Makiko Kumagai-Braesch; Kjell Hultenby; Birger Christensson; Bo-Göran Ericzon; Jan Holgersson; Suchitra Sumitran-Holgersson
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

9.  Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity.

Authors:  E Röther; D Metzger; B Lang; I Melchers; H H Peter
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

10.  Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance.

Authors:  B Preuss; C Berg; F Altenberend; M Gregor; S Stevanovic; R Klein
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.